There are a number of ways that companies can get involved with and help support the Cancer Research Institute's work to bring life-saving new immune-based therapies to patients.
The Cancer Research Institute can be a valuable partner to companies seeking cause-related marketing or sponsorship opportunities. In addition to our annual meetings, companies can also provide sponsorship for pages or areas of our website or can become involved as a sponsor or workplace partner for Cancer Immunotherapy Awareness Month in June and its related fundraising initiative, Wear White for a Cure. For more information, please email Brian Brewer, director of marketing & communications, at firstname.lastname@example.org.
The Cancer Research Institute is a proud member of the Community Health Charities of America (CHC) and United Way. Through the CHC and United Way, we can help you set up an annual giving campaign in your workplace, or enhance one already in place. Your employees will not only contribute to America's most worthy health charities, but also will gain access to special resources including video podcasts on healthy living. To learn more about this, contact Alfred R. Massidas at email@example.com or 212-688-7515 x237.
Cancer Immunotherapy Consortium (CIC)
CRI's Cancer Immunotherapy Consortium is a membership organization of academic institutions and industry companies that share a commitment to overcoming obstacles in the development of cancer immunotherapies. Through workshops and initiatives aimed at developing actionable solutions to clinical development challenges, the CIC delivers tangible outcomes to its members and to the field. Become a member today and help accelerate the discovery and development of effective cancer immunotherapies. Learn More
Through our Clinical Accelerator, companies can gain access to our unique resources, including propriety reagents, expert clinical trials management, field-wide insights from clinical program leadership, and our global cancer immunotherapy clinical trials network, in exchange for access to their reagents for testing in high-priority combination clinical trials. Funding for trials is provided by the Cancer Research Institute's Venture Fund. Learn More